SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-15.7%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$691M
AUM Growth
+$691M
(-9.7%)
Cap. Flow
-$18.3M
Cap. Flow
% of AUM
-2.65%
Top 10 Holdings %
Top 10 Hldgs %
39.75%
Holding
133
New
22
Increased
30
Reduced
31
Closed
35
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
$29.8M |
| 2 |
AstraZeneca
AZN
|
$19.6M |
| 3 |
Palo Alto Networks
PANW
|
$17.5M |
| 4 |
Ituran Location and Control
ITRN
|
$14.6M |
| 5 |
Viatris
VTRS
|
$9.65M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$44.9M |
| 2 |
Merck
MRK
|
$23.5M |
| 3 |
GSK
GSK
|
$21.2M |
| 4 |
Microsoft
MSFT
|
$8.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$8.53M |
Sector Composition
| 1 | Healthcare | 77.38% |
| 2 | Technology | 15.67% |
| 3 | Industrials | 3.75% |
| 4 | Consumer Discretionary | 0.67% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $46M | 5.18% | 1,677,241 +352,241 | +27% | +$9.65M |
|
|
2
Merck
MRK
$210B
| $36.1M | 4.07% | 472,000 -308,000 | -39% | -$23.5M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $32.7M | 3.69% | 630,000 +90,000 | +17% | +$4.68M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $29.8M | 3.36% | +465,000 | New | +$29.8M |
|
5
Caesarstone
CSTE
$49.1M
| $23.8M | 2.68% | 469,160 -92,151 | -16% | -$4.68M |
|
6
Verint Systems
VRNT
$1.23B
| $23.6M | 2.66% | 149,100 -1,026 | -0.7% | -$162K |
|
7
Amicus Therapeutics
FOLD
$2.34B
| $23.5M | 2.64% | 2,447,994 +660,000 | +37% | +$6.32M |
|
8
Gilead Sciences
GILD
$140B
| $21.9M | 2.47% | 350,000 -70,000 | -17% | -$4.38M |
|
|
9
AstraZeneca
AZN
$248B
| $19.6M | 2.2% | +515,000 | New | +$19.6M |
|
|
10
Microsoft
MSFT
$3.77T
| $17.8M | 2.01% | 46,998 -22,658 | -33% | -$8.6M |
|
|
11
Palo Alto Networks
PANW
$127B
| $17.5M | 1.97% | +24,885 | New | +$17.5M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $16.4M | 1.84% | 168,100 +26,400 | +19% | +$2.57M |
|
|
13
Ituran Location and Control
ITRN
$671M
| $14.6M | 1.65% | +122,177 | New | +$14.6M |
|
|
BLUE
14
DELISTED
bluebird bio
BLUE
| $13.8M | 1.55% | 138,796 +60,400 | +77% | +$5.99M |
|
15
Allot
ALLT
$362M
| $13.5M | 1.52% | 595,764 +219,313 | +58% | +$4.97M |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $12.7M | 1.43% | 116,517 +40,401 | +53% | +$4.41M |
|
|
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.4M | 1.4% | 221,269 +128,550 | +139% | +$7.21M |
|
18
PTC Therapeutics
PTCT
$3.92B
| $11.9M | 1.34% | 345,500 +135,500 | +65% | +$4.65M |
|
|
19
GSK
GSK
$79.9B
| $11.8M | 1.34% | 310,000 -555,000 | -64% | -$21.2M |
|
20
Teva Pharmaceuticals
TEVA
$21.1B
| $10.9M | 1.22% | 704,500 +504,500 | +252% | +$7.78M |
|
21
Aldeyra Therapeutics
ALDX
$351M
| $10.2M | 1.15% | 1,232,089 +90,000 | +8% | +$747K |
|
|
IMMU
22
DELISTED
Immunomedics Inc
IMMU
| $10.1M | 1.14% | 706,539 +7,500 | +1% | +$107K |
|
|
SAGE
23
DELISTED
Sage Therapeutics
SAGE
| $9.91M | 1.12% | 103,500 +43,500 | +73% | +$4.17M |
|
|
MLNX
24
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $9.79M | 1.1% | 28,351 -21,742 | -43% | -$7.51M |
|
25
argenx
ARGX
$43.6B
| $8.37M | 0.94% | 87,081 -49,300 | -36% | -$4.74M |
|